Citadel Advisors’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$22.1M Buy
113,000
+65,700
+139% +$12.8M ﹤0.01% 2212
2025
Q4
$8.21M Sell
47,300
-13,600
-22% -$2.48M ﹤0.01% 3514
2025
Q3
$11.6M Sell
60,900
-17,200
-22% -$3.05M ﹤0.01% 3051
2025
Q2
$14M Sell
78,100
-11,600
-13% -$2.01M ﹤0.01% 2595
2025
Q1
$15.2M Buy
89,700
+21,200
+31% +$3.48M ﹤0.01% 2345
2024
Q4
$10.3M Sell
68,500
-16,100
-19% -$2.5M ﹤0.01% 2941
2024
Q3
$13.1M Sell
84,600
-35,700
-30% -$5.33M ﹤0.01% 2545
2024
Q2
$16.5M Buy
120,300
+20,300
+20% +$2.78M ﹤0.01% 2204
2024
Q1
$13.3M Sell
100,000
-15,200
-13% -$1.97M ﹤0.01% 2558
2023
Q4
$15.9M Sell
115,200
-24,700
-18% -$3.25M ﹤0.01% 2263
2023
Q3
$17M Buy
139,900
+57,500
+70% +$7.66M ﹤0.01% 2036
2023
Q2
$11.6M Sell
82,400
-44,800
-35% -$6.18M ﹤0.01% 2483
2023
Q1
$18M Sell
127,200
-45,100
-26% -$6.45M ﹤0.01% 2032
2022
Q4
$27M Buy
172,300
+37,000
+27% +$5.32M 0.01% 1654
2022
Q3
$16.6M Sell
135,300
-44,300
-25% -$5.83M ﹤0.01% 2096
2022
Q2
$23.9M Sell
179,600
-1,600
-0.9% -$218K 0.01% 1663
2022
Q1
$24.8M Buy
181,200
+79,000
+77% +$11M 0.01% 1743
2021
Q4
$17.7M Sell
102,200
-125,400
-55% -$19.1M ﹤0.01% 2177
2021
Q3
$33.1M Buy
227,600
+136,800
+151% +$20M 0.01% 1482
2021
Q2
$12M Buy
90,800
+74,700
+464% +$9.78M ﹤0.01% 2805
2021
Q1
$2.07M Sell
16,100
-34,900
-68% -$4.3M ﹤0.01% 6304
2020
Q4
$6.08M Sell
51,000
-53,000
-51% -$6.46M ﹤0.01% 3356
2020
Q3
$11.9M Sell
104,000
-48,300
-32% -$5.71M ﹤0.01% 2087
2020
Q2
$17.4M Buy
152,300
+63,800
+72% +$6.77M 0.01% 1639
2020
Q1
$7.11M Buy
88,500
+42,900
+94% +$4.44M ﹤0.01% 2264
2019
Q4
$4.87M Sell
45,600
-27,000
-37% -$2.82M ﹤0.01% 3114
2019
Q3
$7.77M Buy
72,600
+9,000
+14% +$924K ﹤0.01% 2535
2019
Q2
$6.47M Sell
63,600
-60,600
-49% -$5.82M ﹤0.01% 2727
2019
Q1
$11.2M Buy
124,200
+40,100
+48% +$3.47M 0.01% 1933
2018
Q4
$7M Buy
84,100
+46,200
+122% +$4.33M ﹤0.01% 2322
2018
Q3
$4.09M Buy
37,900
+8,700
+30% +$954K ﹤0.01% 3260
2018
Q2
$3.21M Sell
29,200
-3,800
-12% -$396K ﹤0.01% 3385
2018
Q1
$3.31M Buy
33,000
+11,800
+56% +$1.21M ﹤0.01% 3004
2017
Q4
$2.09M Sell
21,200
-21,900
-51% -$2.08M ﹤0.01% 3578
2017
Q3
$4.04M Buy
43,100
+23,000
+114% +$2.44M ﹤0.01% 2529
2017
Q2
$2.23M Buy
20,100
+5,300
+36% +$560K ﹤0.01% 3037
2017
Q1
$1.45M Sell
14,800
-18,000
-55% -$1.72M ﹤0.01% 3466
2016
Q4
$3.01M Buy
32,800
+15,600
+91% +$1.34M ﹤0.01% 2495
2016
Q3
$1.46M Sell
17,200
-15,000
-47% -$1.26M ﹤0.01% 3355
2016
Q2
$2.62M Sell
32,200
-15,200
-32% -$1.16M ﹤0.01% 2453
2016
Q1
$3.39M Buy
47,400
+19,200
+68% +$1.29M ﹤0.01% 2142
2015
Q4
$2.01M Buy
28,200
+6,400
+29% +$430K ﹤0.01% 2737
2015
Q3
$1.34M Sell
21,800
-8,800
-29% -$615K ﹤0.01% 3431
2015
Q2
$2.22M Buy
30,600
+5,400
+21% +$399K ﹤0.01% 2947
2015
Q1
$1.94M Sell
25,200
-18,900
-43% -$1.35M ﹤0.01% 3106
2014
Q4
$2.96M Buy
44,100
+20,800
+89% +$1.31M ﹤0.01% 2490
2014
Q3
$1.41M Sell
23,300
-7,500
-24% -$462K ﹤0.01% 3271
2014
Q2
$1.81M Sell
30,800
-300
-1% -$17.6K ﹤0.01% 2822
2014
Q1
$1.8M Buy
31,100
+1,100
+4% +$59K ﹤0.01% 2761
2013
Q4
$1.61M Buy
30,000
+14,000
+88% +$830K ﹤0.01% 2760
2013
Q3
$989K Sell
16,000
-500
-3% -$29.9K ﹤0.01% 3134
2013
Q2
$1M Buy
+16,500
New +$983K ﹤0.01% 3188

Other funds holding DGX

Citadel Advisors's DGX Position: Q1 2026 in Review

Citadel Advisors reduced its Quest Diagnostics (DGX) stake by 18% in Q1 2026, selling an estimated $15.2M and leaving 347,218 shares worth $68M. The position accounts for 0.01% of the portfolio, ranked #1103.

Citadel Advisors first reported a position in DGX in Q2 2013 and has held it in 49 quarters since. The position peaked at $165M in Q4 2014. 1,063 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • Citadel Advisors held 347,218 shares of Quest Diagnostics worth $68M as of Q1 2026.
  • Citadel Advisors sold 78,018 Quest Diagnostics shares in Q1 2026, an estimated $15.2M.
  • Quest Diagnostics made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1103 holding.
  • Citadel Advisors first reported a position in Quest Diagnostics in Q2 2013 and has held it in 49 quarters since.
  • Citadel Advisors's Quest Diagnostics position peaked at $165M in Q4 2014.
  • 1,063 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.